Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week cycles (n = 8) of bortezomib 1.0 or 1.3 mg/m(2) (days 1, 4, 8, 11), lenalidomide 15 to 25 mg (days 1-14), and dexamethasone 40 or 20 mg (days 1,...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Richardson, Paul G., Weller, Edie, Lonial, Sagar, Jakubowiak, Andrzej J., Jagannath, Sundar, Raje, Noopur S., Avigan, David E., Xie, Wanling, Ghobrial, Irene M., Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Joyce, Robin, Kaufman, Jonathan L., Doss, Deborah, Warren, Diane L., Lunde, Laura E., Kaster, Sarah, DeLaney, Carol, Hideshima, Teru, Mitsiades, Constantine S., Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2010
Sujets:
Plenary Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3324254/
https://ncbi.nlm.nih.gov/pubmed/20385792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-02-268862
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires